Alnylam pushes RNAi program into PhI; Aveo takes a smaller office in Cambridge;

@FierceBiotech: The FierceBiotech panel: Top research execs tackle the fast-changing field of cancer drug R&D at BIO 2015. More | Follow @FierceBiotech

@JohnCFierce: This should be interesting: Can PureTech and its high-profile board raise $160M in London? More | Follow @JohnCFierce

> Cambridge, MA-based Alnylam ($ALNY) launched a Phase I clinical trial with ALN-AS1, an RNAi therapy targeting aminolevulinic acid synthase 1 for the treatment of acute hepatic porphyrias. Release

> Aveo Oncology ($AVEO) is relocating into smaller offices, taking 5,000 square feet at One Broadway in Cambridge, MA. Release

Medical Device News

@FierceMedDev: ICYMI: Sequenom stares down suit from Indian genomics firm. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: ICYMI: NIH announces winning teams of Neuro Startup Challenge to commercialize its inventions. Report | Follow @VarunSaxena2

@EmilyWFierce: Study: Gilead's Harvoni could save U.S. and Europe billions in worker productivity. More from FiercePharma | Follow @EmilyWFierce

> SI-Bone raises $21M, brings on new CFO to grow iFuse implant sales. More

> Strong data from Medtronic's latest TAVR caps excellent week for the devices at European conference. Report

Pharma News

@FiercePharma: Bionic turtle offers glimpse into future of 3-D printing. FierceAnimalHealth story | Follow @FiercePharma

@EricPFierce: ICYMI from FiercePharmaManufacturing: FDA blesses Baxter saline plant in Spain for shipments to U.S. of 0.9% sodium chloride. Article | Follow @EricPFierce

@CarlyHFierce: ICYMI: Want the U.K.'s NHS to quickly adopt new products, drugmakers? There's an office for that. Item | Follow @CarlyHFierce

> Valeant, Actavis on verge of FDA nods in IBS for Xifaxan, eluxadoline. Item

> Investors: GSK chief Witty is safe for now, but one more strike and he's out. More

> The legal death of Actavis' Namenda strategy spells doom for the 'hard switch.' Article

Pharma Manufacturing News

> Law enforcement makes another illegal pharma supply chain bust; 2nd in U.S. in 8 days. More

> Singapore moving to meet pharma manufacturing demand for high-quality water. Report

> Strides Arcolab pays $287M for Aspen Pharmacare's Australian business. Article

> Report: Russia quickly becoming a major source of online fake pharma. Item

> Cipla pulls levalbuterol on FDA warning; Wockhardt removes other drugs on concerns. Story

Animal Health News

> Wal-Mart hailed for leadership on animal welfare. Story

> Animal health, production in St. Joseph, MO, ranks fourth in U.S. metro ag economies. Report

> Patterson posts record quarterly results amid shift toward animal health. Story

> Bionic turtle offers glimpse into future of 3-D printing. Item

> Chicken producer Sanderson says FDA's crackdown on antibiotics lacks 'reliable science.' Article

Biotech IT News

> PatientsLikeMe nabs Merck informatics veteran to lead R&D. More

> Gentleman aims to use 23andMe's R&D blank slate to tip in vivo-in silico testing balance. Story

> Trialbee raises $5M to mount U.S. expansion of online trial enrollment business. Item

> Celgene taps Cypher Genomics to spot biomarkers in datasets. Article

> Hedge fund aims algorithms at pharma patents to sink stocks. Report

Drug Delivery News

> Nanoparticles tagged with amino acids help diagnose glioblastoma to someday target drugs. News

> Pacira's liposomal-encased bupivacaine gets positive reviews at breast cancer conference. Report

> European researchers developing implantable, insulin-controlling capsule to fight diabetes. More

> FDA approves long-acting formulation of J&J schizophrenia med. Item

> Data-gathering insulin pen maker Companion pulls in Series B led by Eli Lilly. Article

Pharma Asia News

> Australia zeroes in on pharma in transfer-pricing probe. News

> Heavyweight Chinese consortium buys San Diego-based Ambrx. Article

> Pakistan seen as hot pharma growth market. Story

> CBMG says China and U.S. growing quickly closer in biotech space. More

> China Medical Systems in Greater China deal with Finland's Faron on respiratory candidate. Article

Suggested Articles

Cancer biotech Zentalis Pharmaceuticals priced its IPO at $165 million, eclipsing the $100 million goal it laid out in early March.

The agreement gives Innovax access to a GSK adjuvant to enhance the immune response triggered by its recombinant protein-based vaccine.

Johnson & Johnson is paying Fate Therapeutics $50 million upfront to collaborate on up to four CAR NK and CAR-T cell therapies.